Ascentage Pharma to Participate in Three Upcoming Investor Conferences
MWN-AI** Summary
Ascentage Pharma Group International, a biopharmaceutical company headquartered in Rockville, Maryland, and Suzhou, China, is scheduled to participate in three upcoming investor conferences. The company is focused on developing innovative therapies for cancer, with a strong portfolio of products targeting significant unmet medical needs.
Management will take part in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, where a presentation is set for 9:20 AM EST. Additionally, the team will engage in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026, starting at 9:50 AM EST. Lastly, one-on-one meetings during the Jefferies Biotech on the Beach Summit are planned for March 10 and 11. Interested parties can access webcasts of these events through the Investor Relations section of Ascentage’s website.
Ascentage boasts a robust pipeline, highlighted by Olverembatinib, a third-generation BCR-ABL1 inhibitor that has received approval in China for treating chronic myeloid leukemia (CML). The company is also advancing its second product, Lisaftoclax, a Bcl-2 inhibitor, which is currently being commercialized for patients with chronic lymphocytic leukemia.
In addition to its strong product pipeline, Ascentage Pharma has formed collaborations with major pharmaceutical companies such as Takeda and AstraZeneca, and is partnered with esteemed research institutions including Dana-Farber Cancer Institute and Mayo Clinic. Their commitment to addressing cancer treatment gaps is underscored by global registrational Phase III trials for both Olverembatinib and Lisaftoclax.
For investors and stakeholders, these upcoming presentations demonstrate Ascentage's commitment to transparency and engagement within the biopharmaceutical community as it continues to expand its innovative treatment solutions.
MWN-AI** Analysis
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) appears well-positioned for further growth and investor interest as it prepares to participate in three upcoming investor conferences. With a rich pipeline of promising oncology therapies, including the third-generation BCR-ABL1 inhibitor Olverembatinib, the company's commitment to addressing significant unmet medical needs makes it a compelling candidate in the biopharmaceutical space.
The firm’s participation in these conferences provides a strategic opportunity to bolster communication with investors and present data regarding its ongoing Phase III trials for both Olverembatinib and Lisaftoclax. Given that both products address critical indications covered by the China National Reimbursement Drug List, Ascentage Pharma may enhance its profile among potential investors who are looking for companies with demonstrated commercialization pathways in major markets.
Moreover, the backing of key partnerships with global giants like Takeda and AstraZeneca underscores Ascentage's credibility and potential for sustainable revenue streams. Investors should also be closely monitoring the outcomes of the ongoing clinical trials, particularly the POLARIS-2 for Olverembatinib and the GLORA studies for Lisaftoclax, as successful results could lead to accelerated FDA approvals and market expansion.
However, investors should approach potential investments with caution. As highlighted in the company’s disclosures, evolving regulatory landscapes and competitive pressures in the biopharmaceutical sector may introduce volatility. It is essential to keep abreast of the risks detailed in Ascentage's SEC filings when considering investment decisions.
In summary, Ascentage Pharma presents an interesting investment opportunity driven by its robust pipeline and strategic industry partnerships. Monitoring upcoming conference presentations and trial outcomes could be pivotal for investors looking to capitalize on the company’s growth trajectory in the increasingly competitive oncology market.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management is scheduled to participate in three upcoming investor conferences.
- Oppenheimer 36th Annual Healthcare Life Sciences Conference: Presentation at 9:20 am EST on February 25th
- TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 am EST on March 4th
- Jefferies Biotech on the Beach Summit: One-on-one meetings on March 10th & 11th
The webcasts for the presentation and fireside chat will be accessed by visiting the Events page in the Investor Relations section of Ascentage’s website.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.
The lead asset, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST patients.
The Company’s second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including BTK inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously cleared by the U.S. FDA, the EMA of the EU, and China CDE.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.
These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Special note regarding forward-looking statements and industry data” in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed “Forward-looking Statements” and “Risk Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Yuly Chen, Senior Investor Relations Director
Ascentage Pharma
IR@ascentage.com
+86 512 85557777
+1 (301) 792-5658
Stephanie Carrington
ICR Healthcare
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
AscentagePR@icrhealthcare.com
+1 (646) 866-4012
FAQ**
How does Ascentage Pharma Group International AAPG plan to leverage its partnerships with top biotechnology firms to enhance its pipeline of cancer therapies in both Rockville, Md. and Suzhou, China?
What specific strategies is Ascentage Pharma Group International AAPG utilizing to navigate the regulatory environments in Rockville, Md., and Suzhou, China for its drug approvals and clinical trials?
In light of the investor conferences mentioned, what key milestones is Ascentage Pharma Group International AAPG aiming to achieve that could potentially impact its stock performance in both markets?
How does Ascentage Pharma Group International AAPG assess and address unmet medical needs in cancer treatment within the diverse healthcare landscapes of Rockville, Md., and Suzhou, China?
**MWN-AI FAQ is based on asking OpenAI questions about Ascentage Pharma Group International (NASDAQ: AAPG).
NASDAQ: AAPG
AAPG Trading
9.32% G/L:
$24.0506 Last:
2,515 Volume:
$23.83 Open:
